nytimes.com / .nytimes-com-health / Page 5

In moving to ban a potent synthetic version of kratom, the president's team paved the way for more sales for makers of rival botanic supplements, who had aggressively lobbied for the change.

The lawsuit argues that new federal rules went beyond what Congress enacted and broke from guidance that the federal government previewed to states.

A law meant to end surprise medical billing has led to large paydays for some surgical assistants, who can earn far more than the doctors they help.

The order, which calls for studying the health risks of pesticides in the food supply, does not involve new federal funding, and does not call for regulations or legislation.

Most of the people testing positive for Ebola in the Democratic Republic of Congo are not on health workers' radar, suggesting that contact tracing is lagging dangerously behind.

In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors "no longer have confidence in the integrity of the results."

A cache of internal emails offers a look at the pressure the nation's public health officials faced from the new health secretary in the early months of the Trump administration.

The court's decision is likely to determine the future of thousands of lawsuits against Bayer, which manufactures the weedkiller, over similar claims.

Doctors are contending with low supplies and unfilled orders of generic chemotherapy infusions that are central to the treatment of a long list of cancers.

Scientists believe that the Bundibugyo virus persists in an animal species, occasionally spilling over into humans. But they have yet to identify the species.